GRACEcast
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (audio)
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:06:38
- More information
Informações:
Synopsis
Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.
